WHO ICTRP trial
A Dose-Escalating Phase I/II Study in Patients with RAS-Mutated Metastatic…
NL-OMON54073 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON54073 |
|---|---|
| Public title | A Dose-Escalating Phase I/II Study in Patients with RAS-Mutated Metastatic Colorectal Cancer to Investigate Safety and Clinical Activity of the Triple Combination of: MEK-inhibitor binimetinib, Pan-EGFR inhibitor lapatinib and the Microtubule Targeting Agent (MTA) vinorelbine. |
| Scientific title | A Dose-Escalating Phase I/II Study in Patients with RAS-Mutated Metastatic Colorectal Cancer to Investigate Safety and Clinical Activity of the Triple Combination of: MEK-inhibitor binimetinib, Pan-EGFR inhibitor lapatinib and the Microtubule Targeting Agent (MTA) vinorelbine. - RASTRIC Trial |
| Primary sponsor | Universitair Medisch Centrum Utrecht |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Countries | The Netherlands |
| Conditions | RAS-mutated metastatic colorectal cancer;10017991;RAS-mutated metastatic colorectal cancer |
| Interventions | In the initial dose levels, a rest week schedule was tested to reach an appropriate level for the three drugs with manageable side-effects. In later dose levels, an every-week schedule is tested to optimize efficacy of the therapy. Rest… |
| Registration date | Aug 7, 2023 |
| Target size | 50 |
| Secondary IDs | 2019-004987-23;NL72638.041.20 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: